Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca To Continue Collaboration With Shionogi On Crestor

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca CEO David Brennan stated Oct. 8 that the company will keep the same relationship with Japanese pharmaceutical company Shionogi, after Shionogi's purchase of American firm Sciele Pharma. Currently, AstraZeneca and Shionogi are collaborating in marketing hyperlipidemia drug Crestor (rosuvustatin). Brennan also disclosed that the company will keep the current staff level of 3,200 in Japan, amid its effort to cut work force and streamline operations in the U.S. and Europe. Shionogi launched the take over bid for Sciele in September and completed the bid Oct. 6 in an effort to strengthen the company's sales network in the U.S. market. (Click here for more - Japanese language) "AstraZeneca To Continue The Same Relationship With Shionogi - AstraZeneca CEO" - Nikkei Sangyo News (10/8/08)

You may also be interested in...

One Hundred Years Later, Eli Lilly And Shionogi Hold Onto Cross-Pacific Partnership

Indianapolis-based Eli Lilly has been able to maintain a partnership with Osaka-headquartered Shionogi for exactly one century. Their relationship started when Shionogi started importing gelatin capsules from Lilly back in 1909. Alliance managers from Lilly and Shionogi sat down with PharmAsia News' Tokyo bureau to talk about what has made the partnership so successful.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts